Skip to content

Released May 8, 2025, before the open

10-Q filed May 8, 2025, 38 days after period end · 0001171843-25-002953

Q1 2025 · 10-Q
Revenue—
Net Income-$16.63MN/M vs Q1 2024N/M vs Q4 2024
EPS, diluted—
Operating Income-$17,966,000N/M
Operating Cash Flow-$13,208,000N/M
Free Cash Flowderived-$13,226,000N/M

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Net Income-$16.63M-$10.79M-$7.84M-$7.16M
EPS Diluted———-$0.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR